Literature DB >> 27749253

Development and validation of HPLC and CE methods for simultaneous determination of amlodipine and atorvastatin in the presence of their acidic degradation products in tablets.

Said A Hassan, Eman S Elzanfaly, Salem Badr A El-Zeany, Maissa Y Salem.   

Abstract

Two methods were developed for separation and quantitation of amlodipine (AML) and atorvastatin (ATV) in the presence of their acidic degradation products. The first method was a simple isocratic RP-HPLC method while the second was capillary electrophoresis (CE). Degradation products were obtained by acidic hydrolysis of the two drugs and their structures were elucidated for the first time by IR and MS spectra. Degradation products did not interfere with the determination of either drug and the assays were therefore stability-indicating. The linearity of the proposed methods was established over the ranges 1-50 μg mL-1 for AML and ATV in the HPLC method and in the range of 3-50 and 4-50 μg mL-1 for AML and ATV, respectively, in the CE method. The proposed methods were validated according to ICH guidelines. The methods were successfully applied to estimation of AML and ATV in combined tablets.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27749253     DOI: 10.1515/acph-2016-0040

Source DB:  PubMed          Journal:  Acta Pharm        ISSN: 1330-0075            Impact factor:   2.230


  2 in total

1.  A Fast and Validated Reversed-Phase HPLC Method for Simultaneous Determination of Simvastatin, Atorvastatin, Telmisartan and Irbesartan in Bulk Drugs and Tablet Formulations.

Authors:  Hassan A Alhazmi; Ahmed M Alnami; Mohammed A A Arishi; Raad K Alameer; Mohammed Al Bratty; Zia Ur Rehman; Sadique A Javed; Ismail A Arbab
Journal:  Sci Pharm       Date:  2017-12-19

2.  Characterization of two new degradation products of atorvastatin calcium formed upon treatment with strong acids.

Authors:  Jürgen Krauß; Monika Klimt; Markus Luber; Peter Mayer; Franz Bracher
Journal:  Beilstein J Org Chem       Date:  2019-09-02       Impact factor: 2.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.